|Page (1) of 1 - 09/18/17||email article||print page|
Aduro Biotech to Present at Three Investor Conferences in the Second Half of September(September 18, 2017)
BERKELEY, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Aduro management will present at three investor conferences in New York, NY in the second half of September 2017.
- Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 8:30 am Eastern Time
- Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 8:35 am Eastern Time
- Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Thursday, September 28, 2017 at 1:00 pm Eastern Time
To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit Aduro's website at www.aduro.com.
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, gastric, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patients tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduros B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and preclinical development, including BION-1301, an anti-APRIL antibody. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Sylvia Wheeler SVP, Corporate Affairs
510 809 2137